Leerink Partnrs Has Strong Forecast for NAMS FY2028 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Analysts at Leerink Partnrs raised their FY2028 earnings estimates for NewAmsterdam Pharma in a report released on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn $0.44 per share for the year, up from their prior forecast of $0.39. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($2.06) per share.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.30. The firm had revenue of $29.11 million during the quarter, compared to analysts’ expectations of $5.35 million.

Other equities research analysts also recently issued reports about the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday. Finally, Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $33.80.

NewAmsterdam Pharma Stock Performance

NAMS opened at $22.64 on Friday. NewAmsterdam Pharma has a twelve month low of $8.64 and a twelve month high of $26.35. The firm’s 50-day moving average price is $17.51 and its 200 day moving average price is $18.49.

Insider Buying and Selling

In other news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently bought and sold shares of NAMS. Banque Cantonale Vaudoise acquired a new position in shares of NewAmsterdam Pharma during the second quarter worth approximately $38,000. Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma during the second quarter worth $194,000. Wolverine Asset Management LLC raised its stake in NewAmsterdam Pharma by 117.7% during the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after acquiring an additional 8,394 shares in the last quarter. Sei Investments Co. raised its stake in NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after acquiring an additional 8,087 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new stake in shares of NewAmsterdam Pharma during the third quarter worth $700,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.